Robert M. Bigsby
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Robert M. Bigsby has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Andrea Caperell-Grant
Department of Obstetrics and Gynecology, Indiana University School of Medicine, 975 West Walnut Street (IB360), Indianapolis, IN 46202-5121, USA
6 shared publicationsBailin Tan
Department of Obstetrics and Gynecology Indiana University School of Medicine 975 West Walnut Street (IB360) 46202-5121 Indianapolis Indiana USA
2 shared publicationsMinerva Mercado-Feliciano
Department of Pharmacology and Toxicology
2 shared publicationsXinghua Long
Department of Obstetrics and Gynecology University School of Medicine975 West Walnut Street (IB360), Indianapolis, Indiana 46202, USA1Department of Medical Sciences ProgramIndiana University School of Medicine, Bloomington, Indianapolis, Indiana 47405, USA2Department of SurgeryIndiana University School of Medicine, Indianapolis, Indiana 46202, USA
2 shared publicationsAndrea Caperell–Grant
Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, IN 46228; and ‡Chemoprevention Center, University of Alabama, Birmingham, AL 35294
1 shared publicationChristopher R. LaPensee
University of Cincinnati Medical School, Cincinnati, OH, USA
1 shared publication
Latest Publications
- Open Access
- 23 May 2011
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 32 (8) , 1162-1166
The role for estrogen receptor-alpha and prolactin receptor in sex-dependent DEN-induced liver tumorigenesis
Mice treated neonatally with diethylnitrosamine (DEN) develop liver tumors in a male-dominant manner, reflecting the male bias in human hepatocellular carcinoma. Evidence suggests that estrogen, androgen, prolactin (PRL) and growth hormone (GH) modify liver tumorigenesis. We determined the roles of estrogen receptor-α (ERα) and prolactin receptor (PRLR) using receptor null mice, ERαKO (C57Bl/6J) and PRLR-KO (129Ola-X-C57BL/6), in the neonatal-DEN model of liver tumorigenesis. In both mouse strains, females had reduced tumorigenesis compared with males ( P < 0.01), regardless of ERα or PRLR status. Tumorigenesis was not affected by ovariectomy in C57Bl/6J mice but it was increased by ovariectomy in the mixed strain, 129Ola-X-C57BL/6, regardless of PRLR status. ERαKO males had 47% fewer tumors than ERα wild-type males ( P < 0.01). On the other hand, estradiol treatment protected against tumorigenesis in males only in the presence of ERα. As evidenced by liver gene expression, lack of ERα did not alter the pattern of GH secretion in males but resulted in the male GH pattern in females. These observations indicate that ERα is not required for lower tumorigenesis in females, but it is required for the protective effects of exogenously delivered estradiol. Unexpectedly, the results indicate that ERα plays a role in promotion of liver tumors in males. In addition, it can be concluded that sex differences in liver tumorigenesis cannot be explained by the sexually dimorphic pattern of GH secretion. The results also rule out PRL as the mediator of the protective effect of the ovaries.
- 23 May 2011
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 32 (8) , 1162-1166
Open AccessThe role for estrogen receptor-alpha and prolactin receptor in sex-dependent DEN-induced liver tumorigenesis
Mice treated neonatally with diethylnitrosamine (DEN) develop liver tumors in a male-dominant manner, reflecting the male bias in human hepatocellular carcinoma. Evidence suggests that estrogen, androgen, prolactin (PRL) and growth hormone (GH) modify liver tumorigenesis. We determined the roles of estrogen receptor-α (ERα) and prolactin receptor (PRLR) using receptor null mice, ERαKO (C57Bl/6J) and PRLR-KO (129Ola-X-C57BL/6), in the neonatal-DEN model of liver tumorigenesis. In both mouse strains, females had reduced tumorigenesis compared with males ( P < 0.01), regardless of ERα or PRLR status. Tumorigenesis was not affected by ovariectomy in C57Bl/6J mice but it was increased by ovariectomy in the mixed strain, 129Ola-X-C57BL/6, regardless of PRLR status. ERαKO males had 47% fewer tumors than ERα wild-type males ( P < 0.01). On the other hand, estradiol treatment protected against tumorigenesis in males only in the presence of ERα. As evidenced by liver gene expression, lack of ERα did not alter the pattern of GH secretion in males but resulted in the male GH pattern in females. These observations indicate that ERα is not required for lower tumorigenesis in females, but it is required for the protective effects of exogenously delivered estradiol. Unexpectedly, the results indicate that ERα plays a role in promotion of liver tumors in males. In addition, it can be concluded that sex differences in liver tumorigenesis cannot be explained by the sexually dimorphic pattern of GH secretion. The results also rule out PRL as the mediator of the protective effect of the ovaries.
- 1 January 2011
- Published by Radiation Research Society in Radiation Research
- Vol. 175 (1) , 37-43
Age and Hormonal Status as Determinants of Cataractogenesis Induced by Ionizing Radiation. I. Densely Ionizing (High-LET) Radiation
Astronauts participating in extended lunar missions or the projected mission to Mars would likely be exposed to significant doses of high-linear energy transfer (LET) heavy energetic charged (HZE) particles. Exposure to even relatively low doses of such space radiation may result in a reduced latent period for and an increased incidence of lens opacification. However, the determinants of cataractogenesis induced by densely ionizing radiation have not been clearly elucidated. In the current study, we show that age at the time of exposure is a key determinant of cataractogenesis in rats whose eyes have been exposed to 2 Gy of (56)Fe ions. The rate of progression of cataractogenesis was significantly greater in the irradiated eyes of 1-year-old rats compared to young (56-day-old) rats. Furthermore, older ovariectomized rats that received exogenous estrogen treatment (17-β-estradiol) commencing 1 week prior to irradiation and continuing throughout the period of observation of up to approximately 600 days after irradiation showed an increased incidence of cataracts and faster progression of opacification compared to intact rats with endogenous estrogen or ovariectomized rats. The same potentiating effect (higher incidence, reduced latent period) was observed for irradiated eyes of young rats. Modulation of estrogen status in the 1-year-old animals (e.g., removal of estrogen by ovariectomy or continuous exposure to estrogen) did not increase the latent period or reduce the incidence to that of intact 56-day-old rats. Since the rapid onset and progression of cataracts in 1-year-old compared to 56-day-old rats was independent of estrogen status, we conclude that estrogen cannot account for the age-dependent differences in cataractogenesis induced by high-LET radiation.
- 1 January 2011
- Published by Radiation Research Society in Radiation Research
- Vol. 175 (1) , 37-43
Age and Hormonal Status as Determinants of Cataractogenesis Induced by Ionizing Radiation. I. Densely Ionizing (High-LET) Radiation
Astronauts participating in extended lunar missions or the projected mission to Mars would likely be exposed to significant doses of high-linear energy transfer (LET) heavy energetic charged (HZE) particles. Exposure to even relatively low doses of such space radiation may result in a reduced latent period for and an increased incidence of lens opacification. However, the determinants of cataractogenesis induced by densely ionizing radiation have not been clearly elucidated. In the current study, we show that age at the time of exposure is a key determinant of cataractogenesis in rats whose eyes have been exposed to 2 Gy of (56)Fe ions. The rate of progression of cataractogenesis was significantly greater in the irradiated eyes of 1-year-old rats compared to young (56-day-old) rats. Furthermore, older ovariectomized rats that received exogenous estrogen treatment (17-β-estradiol) commencing 1 week prior to irradiation and continuing throughout the period of observation of up to approximately 600 days after irradiation showed an increased incidence of cataracts and faster progression of opacification compared to intact rats with endogenous estrogen or ovariectomized rats. The same potentiating effect (higher incidence, reduced latent period) was observed for irradiated eyes of young rats. Modulation of estrogen status in the 1-year-old animals (e.g., removal of estrogen by ovariectomy or continuous exposure to estrogen) did not increase the latent period or reduce the incidence to that of intact 56-day-old rats. Since the rapid onset and progression of cataracts in 1-year-old compared to 56-day-old rats was independent of estrogen status, we conclude that estrogen cannot account for the age-dependent differences in cataractogenesis induced by high-LET radiation.
- Open Access
- 1 October 2008
- Published by American Chemical Society (ACS) in Environmental Health Perspectives
- Vol. 116 (10) , 1315-1321
Hydroxylated Metabolites of the Polybrominated Diphenyl Ether Mixture DE-71 Are Weak Estrogen Receptor-α Ligands
Background: Polybrominated diphenyl ethers (PBDEs) are widely found in the environment and are suspected endocrine disruptors. We previously identified six hydroxylated metabolites of PBDE (OH-PBDEs) in treated mice. Objective: We tested the hypothesis that OH-PBDEs would interact with and alter activity of estrogen receptor-α (ER-α). Methods: We tested estrogenicity using two assays: 3H-estradiol (3H-E2) displacement from recombinant ER-α and induction of reporter gene (ERE-luciferase) in cultured cells. We incubated the PBDE mixture DE-71 with rat liver microsomes and tested the resultant metabolite mixture for estrogenic activity. We also determined relative estrogenic potential of individual hydroxylated PBDE congeners. Results: Reporter gene activity was increased by DE-71 that had been subjected to microsomal metabolism. DE-71 did not displace E2 from ER-α, but all six of the OH-PBDE metabolites did. para-Hydroxylated metabolites displayed a 10- to 30-fold higher affinity for ER-α compared with ortho-hydroxylated PBDEs, and one produced a maximal effect 30% higher than that produced by E2. Coadministration of E2 and DE-71, or certain of its metabolites, yielded reporter activity greater than either chemical alone. Two ortho-OH-PBDEs were antiestrogenic in the reporter assay. Conclusions: The observations—that the DE-71 mixture did not displace 3H-E2 from ER-α while the hydroxylated metabolites did—suggest that the weak estrogenic effects of DE-71 are due to metabolic activation of individual congeners. However, the behavior of DE-71 and its metabolites, when co-administered with E2, suggest a secondary, undetermined mechanism from classical ER-α activation.
- 1 October 2008
- Published by American Chemical Society (ACS) in Environmental Health Perspectives
- Vol. 116 (10) , 1315-1321
Open AccessHydroxylated Metabolites of the Polybrominated Diphenyl Ether Mixture DE-71 Are Weak Estrogen Receptor-α Ligands
Background: Polybrominated diphenyl ethers (PBDEs) are widely found in the environment and are suspected endocrine disruptors. We previously identified six hydroxylated metabolites of PBDE (OH-PBDEs) in treated mice. Objective: We tested the hypothesis that OH-PBDEs would interact with and alter activity of estrogen receptor-α (ER-α). Methods: We tested estrogenicity using two assays: 3H-estradiol (3H-E2) displacement from recombinant ER-α and induction of reporter gene (ERE-luciferase) in cultured cells. We incubated the PBDE mixture DE-71 with rat liver microsomes and tested the resultant metabolite mixture for estrogenic activity. We also determined relative estrogenic potential of individual hydroxylated PBDE congeners. Results: Reporter gene activity was increased by DE-71 that had been subjected to microsomal metabolism. DE-71 did not displace E2 from ER-α, but all six of the OH-PBDE metabolites did. para-Hydroxylated metabolites displayed a 10- to 30-fold higher affinity for ER-α compared with ortho-hydroxylated PBDEs, and one produced a maximal effect 30% higher than that produced by E2. Coadministration of E2 and DE-71, or certain of its metabolites, yielded reporter activity greater than either chemical alone. Two ortho-OH-PBDEs were antiestrogenic in the reporter assay. Conclusions: The observations—that the DE-71 mixture did not displace 3H-E2 from ER-α while the hydroxylated metabolites did—suggest that the weak estrogenic effects of DE-71 are due to metabolic activation of individual congeners. However, the behavior of DE-71 and its metabolites, when co-administered with E2, suggest a secondary, undetermined mechanism from classical ER-α activation.
- Open Access
- 1 June 2008
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 15 (2) , 475-483
Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma
Numerous epidemiological observations point to sex differences in lung cancer etiology and progression. The present study was aimed at understanding the bases of these sex differences. To test the effect of estradiol on tumor progression, we used a mouse model based on conditional Kras expression and concurrent deletion of Tp53 following inhalation of an adenoviral vector expressing Cre recombinase (AdeCre). Ovariectomized females and males were treated with estradiol via a continuous-release capsule. Tumor multiplicity, tumor volume, and histological grade were determined at 10 weeks after AdeCre administration. Cell proliferation was monitored by Ki67 immunohistochemistry at 4 and 10 weeks after AdeCre administration. At 10 weeks, female mice had more than twice the number of tumors evident on the surface of the lungs than male mice; ovariectomy eliminated this sex difference. The estrogen treatment significantly increased tumor number and volume in ovariectomized females and in males. Histological character of the tumors ranged from adenoma to adenocarcinoma. Ovary-intact females exhibited higher grade tumors than ovariectomized females or males. Progression to higher histological grade was stimulated by estrogen in male mice but not in ovariectomized females. At 10 weeks after AdeCre administration, tumor cell Ki67-labeling varied widely, precluding assessment of an estrogen effect; however, at 4 weeks, Ki67 labeling of lung parenchymal cells was increased 3.5-fold by estrogen. In conclusion, estrogen acts as a promoter for lung adenocarcinoma in a genetically defined lung cancer model; estrogen-induced cell proliferation in the oncogene-initiated cells is likely to play a role in this tumor promoter activity.
- 1 June 2008
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 15 (2) , 475-483
Open AccessEstrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma
Numerous epidemiological observations point to sex differences in lung cancer etiology and progression. The present study was aimed at understanding the bases of these sex differences. To test the effect of estradiol on tumor progression, we used a mouse model based on conditional Kras expression and concurrent deletion of Tp53 following inhalation of an adenoviral vector expressing Cre recombinase (AdeCre). Ovariectomized females and males were treated with estradiol via a continuous-release capsule. Tumor multiplicity, tumor volume, and histological grade were determined at 10 weeks after AdeCre administration. Cell proliferation was monitored by Ki67 immunohistochemistry at 4 and 10 weeks after AdeCre administration. At 10 weeks, female mice had more than twice the number of tumors evident on the surface of the lungs than male mice; ovariectomy eliminated this sex difference. The estrogen treatment significantly increased tumor number and volume in ovariectomized females and in males. Histological character of the tumors ranged from adenoma to adenocarcinoma. Ovary-intact females exhibited higher grade tumors than ovariectomized females or males. Progression to higher histological grade was stimulated by estrogen in male mice but not in ovariectomized females. At 10 weeks after AdeCre administration, tumor cell Ki67-labeling varied widely, precluding assessment of an estrogen effect; however, at 4 weeks, Ki67 labeling of lung parenchymal cells was increased 3.5-fold by estrogen. In conclusion, estrogen acts as a promoter for lung adenocarcinoma in a genetically defined lung cancer model; estrogen-induced cell proliferation in the oncogene-initiated cells is likely to play a role in this tumor promoter activity.
- Open Access
- 1 May 2008
- Published by Oxford University Press (OUP) in Biology of Reproduction
- Vol. 78 (Suppl_1) , 61
Pituitary Prolactin Mediates Estrogen-induced Cellular Proliferation in the Uterine Stroma and Myometrium of the Progesterone-primed Mouse.
Hormonal regulation of cellular proliferation plays a key role in preparing the uterus for pregnancy. On the other hand, aberrant hormonal stimulation is associated with several pathological conditions of the uterus. In the progesterone-primed, ovariectomized rodent, estrogen stimulates proliferation of endometrial stromal and myometrial cells; in an earlier report we showed this effect is mediated by production of an estrogen receptor-alpha (ERα)-dependent systemic factor. In this report, we examine the role of prolactin (PRL) in mediating the effect of estrogen on uterine cell proliferation. Following progesterone priming, a single dose of PRL induced cell proliferation in the endometrial stroma and myometrium to the same extent as a single dose of estradiol. In the epithelium, PRL administered alone induced a slight increase in cell proliferation but this was not evident in the progesterone-primed uterus. To examine the role of endogenous pituitary PRL, we grafted ERα-negative mouse uterus to wild-type (ERα-positive), syngeneic hosts and subjected the hosts to the standard progesterone and estrogen treatment, with or without the addition of a single dose of bromocriptine to inhibit estrogen-induced release of pituitary PRL. In the grafted uterus, estrogen stimulated cellular proliferation in the stroma and myometrium and these effects were blocked by bromocriptine. Similarly, bromocriptine blocked estrogen induction of proliferation in the uterine stroma and myometrium of the host but it did not block estrogen-induced proliferation in the uterine epithelium. These observations indicate that estrogen-induced proliferation of mesenchymally derived uterine tissues is mediated by pituitary PRL. This has profound implications for treatment of pathological conditions of the uterus.
- 1 May 2008
- Published by Oxford University Press (OUP) in Biology of Reproduction
- Vol. 78 (Suppl_1) , 61
Open AccessPituitary Prolactin Mediates Estrogen-induced Cellular Proliferation in the Uterine Stroma and Myometrium of the Progesterone-primed Mouse.
Hormonal regulation of cellular proliferation plays a key role in preparing the uterus for pregnancy. On the other hand, aberrant hormonal stimulation is associated with several pathological conditions of the uterus. In the progesterone-primed, ovariectomized rodent, estrogen stimulates proliferation of endometrial stromal and myometrial cells; in an earlier report we showed this effect is mediated by production of an estrogen receptor-alpha (ERα)-dependent systemic factor. In this report, we examine the role of prolactin (PRL) in mediating the effect of estrogen on uterine cell proliferation. Following progesterone priming, a single dose of PRL induced cell proliferation in the endometrial stroma and myometrium to the same extent as a single dose of estradiol. In the epithelium, PRL administered alone induced a slight increase in cell proliferation but this was not evident in the progesterone-primed uterus. To examine the role of endogenous pituitary PRL, we grafted ERα-negative mouse uterus to wild-type (ERα-positive), syngeneic hosts and subjected the hosts to the standard progesterone and estrogen treatment, with or without the addition of a single dose of bromocriptine to inhibit estrogen-induced release of pituitary PRL. In the grafted uterus, estrogen stimulated cellular proliferation in the stroma and myometrium and these effects were blocked by bromocriptine. Similarly, bromocriptine blocked estrogen induction of proliferation in the uterine stroma and myometrium of the host but it did not block estrogen-induced proliferation in the uterine epithelium. These observations indicate that estrogen-induced proliferation of mesenchymally derived uterine tissues is mediated by pituitary PRL. This has profound implications for treatment of pathological conditions of the uterus.
- Open Access
- 1 May 2008
- Published by American Chemical Society (ACS) in Environmental Health Perspectives
- Vol. 116 (5) , 605-611
The Polybrominated Diphenyl Ether Mixture DE-71 Is Mildly Estrogenic
Background: Polybrominated diphenyl ethers (PBDEs) are widely found in the environment, and they may act as endocrine disruptors. Objective: Our goal in this study was to test the PBDE mixture DE-71 for estrogenic activity. Methods: We used proliferation of cultured breast cancer cells (MCF-7) and trophic effects in the reproductive tracts of ovariectomized mice as estrogen bioassays. DE-71 was administered to mice by subcutaneous injection (sc) or oral gavage (po), alone or in combination with estradiol, for 3 or 34 days. Liver weights and cytochrome P450 enzyme activities were also measured. Results: DE-71 increased MCF-7 cell proliferation, and this was prevented by antiestrogen. DE-71 cotreatment reduced the effect of estradiol in MCF-7 cells. In the mouse 3-day assay, DE-71 administered alone had no effect on uterine weight, uterine epithelial height (UEH), or vaginal epithelial thickness (VET); however, when DE-71 was administered as a cotreatment, it potentiated estradiol’s effect on uterine weight. DE-71 administered sc to BALB/c mice for 34 days slightly increased UEH and VET, and attenuated the estradiol-induced increase in UEH; these effects were not seen in BALB/c mice treated po or in C57BL/6 mice treated sc. DE-71 increased liver weight in BALB/c, C57BL/6, and estrogen receptor-α knockout mice. We also found an increase in liver cytochrome P450 1A (CYP1A) and CYP2B activities when DE-71 was administered po, but only CYP2B increased after sc treatment. Conclusion: DE-71 behaves as a weak estrogen. In mice, the treatment route and duration determined if DE-71 was estrogenic. BALB/c mice are more susceptible to DE-71 effects in estrogen target tissues than C57BL/6 mice. DE-71 increased liver weight independently of estrogen receptor-α.
- 1 May 2008
- Published by American Chemical Society (ACS) in Environmental Health Perspectives
- Vol. 116 (5) , 605-611
Open AccessThe Polybrominated Diphenyl Ether Mixture DE-71 Is Mildly Estrogenic
Background: Polybrominated diphenyl ethers (PBDEs) are widely found in the environment, and they may act as endocrine disruptors. Objective: Our goal in this study was to test the PBDE mixture DE-71 for estrogenic activity. Methods: We used proliferation of cultured breast cancer cells (MCF-7) and trophic effects in the reproductive tracts of ovariectomized mice as estrogen bioassays. DE-71 was administered to mice by subcutaneous injection (sc) or oral gavage (po), alone or in combination with estradiol, for 3 or 34 days. Liver weights and cytochrome P450 enzyme activities were also measured. Results: DE-71 increased MCF-7 cell proliferation, and this was prevented by antiestrogen. DE-71 cotreatment reduced the effect of estradiol in MCF-7 cells. In the mouse 3-day assay, DE-71 administered alone had no effect on uterine weight, uterine epithelial height (UEH), or vaginal epithelial thickness (VET); however, when DE-71 was administered as a cotreatment, it potentiated estradiol’s effect on uterine weight. DE-71 administered sc to BALB/c mice for 34 days slightly increased UEH and VET, and attenuated the estradiol-induced increase in UEH; these effects were not seen in BALB/c mice treated po or in C57BL/6 mice treated sc. DE-71 increased liver weight in BALB/c, C57BL/6, and estrogen receptor-α knockout mice. We also found an increase in liver cytochrome P450 1A (CYP1A) and CYP2B activities when DE-71 was administered po, but only CYP2B increased after sc treatment. Conclusion: DE-71 behaves as a weak estrogen. In mice, the treatment route and duration determined if DE-71 was estrogenic. BALB/c mice are more susceptible to DE-71 effects in estrogen target tissues than C57BL/6 mice. DE-71 increased liver weight independently of estrogen receptor-α.
- Open Access
- 19 February 2008
- Published by Bioscientifica in Journal of Molecular Endocrinology
- Vol. 40 (5) , 199-210
Striatin-3γ inhibits estrogen receptor activity by recruiting a protein phosphatase
A splicing variant of rat striatin-3 (rSTRN3γ) was found to associate with estrogen receptor-α (ERα) in a ligand-dependent manner. In two-hybrid and pull-down analyses, estradiol induced an interaction between rSTRN3γ and ERα. STRN3γ protein was found in nuclear extracts from rat uterus and human cell lines. Overexpression of rSTRN3γ induced a decrease in ERα transcriptional activity but had no effect on ERβ activity. Immunoprecipitation analyses showed that rSTRN3γ interacts with both the ERα and the catalytic subunit of protein phosphatase 2A (PP2A(C)). The transrepressor action of rSTRN3γ was overcome by okadaic acid, an inhibitor of PP2A(C), and by cotransfection of PP2A(C) siRNA. rSTRN3γ caused dephosphorylation of ERα at serine 118 and this was abrogated by okadaic acid. ERα lacking phosphorylation sites at either serine 118 or 167 was insensitive to the corepressor action of rSTRN3γ. These observations suggest that an rSTRN3γ-PP2A(C) complex is recruited to agonist-activated ERα, thereby leading to its dephosphorylation and inhibiting transcription.
- 19 February 2008
- Published by Bioscientifica in Journal of Molecular Endocrinology
- Vol. 40 (5) , 199-210
Open AccessStriatin-3γ inhibits estrogen receptor activity by recruiting a protein phosphatase
A splicing variant of rat striatin-3 (rSTRN3γ) was found to associate with estrogen receptor-α (ERα) in a ligand-dependent manner. In two-hybrid and pull-down analyses, estradiol induced an interaction between rSTRN3γ and ERα. STRN3γ protein was found in nuclear extracts from rat uterus and human cell lines. Overexpression of rSTRN3γ induced a decrease in ERα transcriptional activity but had no effect on ERβ activity. Immunoprecipitation analyses showed that rSTRN3γ interacts with both the ERα and the catalytic subunit of protein phosphatase 2A (PP2A(C)). The transrepressor action of rSTRN3γ was overcome by okadaic acid, an inhibitor of PP2A(C), and by cotransfection of PP2A(C) siRNA. rSTRN3γ caused dephosphorylation of ERα at serine 118 and this was abrogated by okadaic acid. ERα lacking phosphorylation sites at either serine 118 or 167 was insensitive to the corepressor action of rSTRN3γ. These observations suggest that an rSTRN3γ-PP2A(C) complex is recruited to agonist-activated ERα, thereby leading to its dephosphorylation and inhibiting transcription.
- 1 January 2004
- Published by Oxford University Press (OUP) in Biology of Reproduction
- Vol. 70 (1) , 178-183
Estrogen Induces a Systemic Growth Factor Through an Estrogen Receptor-Alpha-Dependent Mechanism1
Estrogen induces proliferation of uterine epithelium through a paracrine action of estrogen receptor (ERα) in the underlying stroma. In ovariectomized mice primed with progesterone, estrogen stimulates proliferation in both the epithelium and the stroma. We set out to test whether a paracrine mode of action is involved in estrogen-induced proliferation of the uterine stroma. Epithelial and mesenchymal tissues derived from uteri of neonatal ERα null mice (ERαKO) or wild-type mice were separated and recombined in all four possible configurations (ERα+ or ERα− epithelium with ERα+ or ERα− mesenchyme) and grafted into female athymic mice. After 5 wk, hosts were ovariectomized and challenged with hormone treatment, and cellular proliferation was monitored by thymidine autoradiography. Results showed that, although the full response of the epithelium was dependent on an ERα-positive mesenchyme, stromal cell proliferation was independent of tissue ERα. This latter observation suggests that the response of the stroma was due to a systemic factor induced in the ERα-positive hosts. To test this possibility, pieces of whole uterus from neonatal wild-type or ERαKO mice were grafted into syngeneic wild-type or ERαKO hosts. In these whole-uterus grafts, estradiol stimulated ERαKO uterine stroma when they were grown in wild-type hosts but not when grown in ERαKO hosts. The epithelium of whole-uterus ERαKO grafts did not respond to estrogen, regardless of the host phenotype. These observations suggest that treatment of progesterone-primed mice with estradiol stimulates production of a systemic factor that is capable of inducing uterine stromal cell proliferation and that this systemic factor is produced by an ERα-dependent mechanism.
- 1 January 2004
- Published by Oxford University Press (OUP) in Biology of Reproduction
- Vol. 70 (1) , 178-183
Estrogen Induces a Systemic Growth Factor Through an Estrogen Receptor-Alpha-Dependent Mechanism1
Estrogen induces proliferation of uterine epithelium through a paracrine action of estrogen receptor (ERα) in the underlying stroma. In ovariectomized mice primed with progesterone, estrogen stimulates proliferation in both the epithelium and the stroma. We set out to test whether a paracrine mode of action is involved in estrogen-induced proliferation of the uterine stroma. Epithelial and mesenchymal tissues derived from uteri of neonatal ERα null mice (ERαKO) or wild-type mice were separated and recombined in all four possible configurations (ERα+ or ERα− epithelium with ERα+ or ERα− mesenchyme) and grafted into female athymic mice. After 5 wk, hosts were ovariectomized and challenged with hormone treatment, and cellular proliferation was monitored by thymidine autoradiography. Results showed that, although the full response of the epithelium was dependent on an ERα-positive mesenchyme, stromal cell proliferation was independent of tissue ERα. This latter observation suggests that the response of the stroma was due to a systemic factor induced in the ERα-positive hosts. To test this possibility, pieces of whole uterus from neonatal wild-type or ERαKO mice were grafted into syngeneic wild-type or ERαKO hosts. In these whole-uterus grafts, estradiol stimulated ERαKO uterine stroma when they were grown in wild-type hosts but not when grown in ERαKO hosts. The epithelium of whole-uterus ERαKO grafts did not respond to estrogen, regardless of the host phenotype. These observations suggest that treatment of progesterone-primed mice with estradiol stimulates production of a systemic factor that is capable of inducing uterine stromal cell proliferation and that this systemic factor is produced by an ERα-dependent mechanism.
- 1 May 2002
- Published by Elsevier in Cancer Letters
- Vol. 179 (2) , 113-119
Synergistic tumor promoter effects of estrone and progesterone in methylnitrosourea-induced rat mammary cancer
- 1 May 2002
- Published by Elsevier in Cancer Letters
- Vol. 179 (2) , 113-119
Synergistic tumor promoter effects of estrone and progesterone in methylnitrosourea-induced rat mammary cancer
- 1 March 2002
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 955 (1) , 110-117
Control of Growth and Differentiation of the Endometrium: The Role of Tissue Interactions
Abstract: Early work with neonatal mice showed that estrogen receptor‐negative uterine epithelium responded to estrogen treatment. Since the underlying mesenchymal cells were estrogen receptor‐positive, it was suggested that these cells mediated the hormonal response through elaboration of a paracrine factor. Cell culture work showed that mesenchymal cells produced soluble factors that stimulate uterine epithelium, but hormonal regulation was absent or minimal. The paracrine hypothesis of estrogen action has been proved by the use of tissue recombinant studies in which epithelium from estrogen receptor‐alpha knockout mice was combined with wild‐type mesenchyme; estrogen stimulated the ERα‐negative epithelium if the underlying stromal cells were receptor‐positive. Also, it is hypothesized that there is a reciprocal paracrine interaction during stimulation with progesterone and estrogen. Accordingly, under progesterone dominance, the epithelium elaborates factors that direct the underlying stroma to proliferate when estrogen is administered. Although this hypothesis needs further testing, it has been shown that the uterine epithelium is required for stromal responsiveness to hormones. The question arises: What are the factors that mediate the effects of the steroid hormones in the uterus? Several peptide growth factors are regulated by estrogen and/or progesterone. Use of knockout animals will allow a determination of the role that these factors play in the uterus. However, ablation of many of these growth factor genes has proved lethal to the newborn animals, making it impossible to study hormonal effects using standard techniques. Tissue xenograft and tissue recombination studies offer a means of defining the role of specific growth factors in uterine physiology.
- 1 March 2002
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 955 (1) , 110-117
Control of Growth and Differentiation of the Endometrium: The Role of Tissue Interactions
Abstract: Early work with neonatal mice showed that estrogen receptor‐negative uterine epithelium responded to estrogen treatment. Since the underlying mesenchymal cells were estrogen receptor‐positive, it was suggested that these cells mediated the hormonal response through elaboration of a paracrine factor. Cell culture work showed that mesenchymal cells produced soluble factors that stimulate uterine epithelium, but hormonal regulation was absent or minimal. The paracrine hypothesis of estrogen action has been proved by the use of tissue recombinant studies in which epithelium from estrogen receptor‐alpha knockout mice was combined with wild‐type mesenchyme; estrogen stimulated the ERα‐negative epithelium if the underlying stromal cells were receptor‐positive. Also, it is hypothesized that there is a reciprocal paracrine interaction during stimulation with progesterone and estrogen. Accordingly, under progesterone dominance, the epithelium elaborates factors that direct the underlying stroma to proliferate when estrogen is administered. Although this hypothesis needs further testing, it has been shown that the uterine epithelium is required for stromal responsiveness to hormones. The question arises: What are the factors that mediate the effects of the steroid hormones in the uterus? Several peptide growth factors are regulated by estrogen and/or progesterone. Use of knockout animals will allow a determination of the role that these factors play in the uterus. However, ablation of many of these growth factor genes has proved lethal to the newborn animals, making it impossible to study hormonal effects using standard techniques. Tissue xenograft and tissue recombination studies offer a means of defining the role of specific growth factors in uterine physiology.